Literature DB >> 6721831

Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4.

D A Lane, J Denton, A M Flynn, L Thunberg, U Lindahl.   

Abstract

Oligosaccharides of well-defined molecular size were prepared from heparin by nitrous acid depolymerization, affinity chromatography on immobilized antithrombin III (see footnote on Nomenclature) and gel chromatography on Sephadex G-50. High affinity (for antithrombin III) octa-, deca-, dodeca-, tetradeca-, hexadeca- and octadeca-saccharides were prepared, as well as oligosaccharides of larger size than octadecasaccharide. The inhibition of Factor Xa by antithrombin III was greatly accelerated by all of these oligosaccharides, the specific anti-Factor Xa activity being invariably greater than 1300 units/mumol. The anti-Factor Xa activity of the decasaccharide was not significantly decreased in the presence of platelet factor 4, even at high platelet factor 4/oligosaccharide ratios. Measurable but incomplete neutralization of the anti-Factor Xa activities of the tetradeca- and hexadeca-saccharides was observed, and complete neutralization of octadeca- and larger oligo-saccharides was achieved with excess platelet factor 4. The octa-, deca-, dodeca-, tetradeca- and hexadeca-saccharides had negligible effect on the inhibition of thrombin by antithrombin III, whereas specific anti-thrombin activity was expressed by the octadeca-saccharide and by the larger oligosaccharides. An octadecasaccharide is therefore the smallest heparin fragment (prepared by nitrous acid depolymerization) that can accelerate thrombin inhibition by antithrombin III. The anti-thrombin activities of the octadecasaccharide and larger oligosaccharides were more readily neutralized by platelet factor 4 than were their anti-Factor Xa activities. These findings are compatible with two alternative mechanisms for the action of platelet factor 4, both involving the binding of the protein molecule adjacent to the antithrombin III-binding site. Such binding results in either steric interference with the formation of antithrombin III-proteinase complexes or in displacement of the antithrombin III molecule from the heparin chain.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6721831      PMCID: PMC1153400          DOI: 10.1042/bj2180725

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  37 in total

1.  A modified uronic acid carbazole reaction.

Authors:  T BITTER; H M MUIR
Journal:  Anal Biochem       Date:  1962-10       Impact factor: 3.365

2.  Platelet antiheparin proteins and antithrombin III interact with different binding sites on heparin molecule.

Authors:  S Niewiarowski; B Rucinski; P James; U Lindahl
Journal:  FEBS Lett       Date:  1979-06-01       Impact factor: 4.124

3.  A differential effect of low-affinity heparin on the inhibition of thrombin and factor Xa by antithrombin.

Authors:  B Nordenman; K Nordling; I Björk
Journal:  Thromb Res       Date:  1980 Feb 1-15       Impact factor: 3.944

4.  Anticoagulant activities and effects on platelets of a heparin fragment with high affinity for antithrombin.

Authors:  E Holmer; U Lindahl; G Bäckström; L Thunberg; H Sandberg; G Söderström; L O Anderson
Journal:  Thromb Res       Date:  1980-06-15       Impact factor: 3.944

5.  The molecular size of the antithrombin-binding sequence in heparin.

Authors:  L Thunberg; G Bäckström; H Grundberg; J Riesenfeld; U Lindahl
Journal:  FEBS Lett       Date:  1980-08-11       Impact factor: 4.124

6.  The anti-heparin properties of human low-density lipoprotein.

Authors:  I R MacGregor; D A Lane; V V Kakkar
Journal:  Biochim Biophys Acta       Date:  1980-03-21

7.  On the molecular-weight-dependence of the anticoagulant activity of heparin.

Authors:  L Thunberg; U Lindahl; A Tengblad; T C Laurent; C M Jackson
Journal:  Biochem J       Date:  1979-07-01       Impact factor: 3.857

8.  Structure of the antithrombin-binding site in heparin.

Authors:  U Lindahl; G Bäckström; M Höök; L Thunberg; L A Fransson; A Linker
Journal:  Proc Natl Acad Sci U S A       Date:  1979-07       Impact factor: 11.205

9.  The binding of low molecular weight heparin to hemostatic enzymes.

Authors:  R E Jordan; G M Oosta; W T Gardner; R D Rosenberg
Journal:  J Biol Chem       Date:  1980-11-10       Impact factor: 5.157

10.  Evidence for a 3-O-sulfated D-glucosamine residue in the antithrombin-binding sequence of heparin.

Authors:  U Lindahl; G Bäckström; L Thunberg; I G Leder
Journal:  Proc Natl Acad Sci U S A       Date:  1980-11       Impact factor: 11.205

View more
  50 in total

1.  Antithrombotic effects of synthetic peptides targeting various functional domains of thrombin.

Authors:  A B Kelly; J M Maraganore; P Bourdon; S R Hanson; L A Harker
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-01       Impact factor: 11.205

Review 2.  The hemostatic defect of cardiopulmonary bypass.

Authors:  Matthew Dean Linden
Journal:  J Thromb Thrombolysis       Date:  2003-12       Impact factor: 2.300

3.  The C-terminal fragment of axon guidance molecule Slit3 binds heparin and neutralizes heparin's anticoagulant activity.

Authors:  Eduard Condac; Heather Strachan; Gerardo Gutierrez-Sanchez; Benjamin Brainard; Christina Giese; Christian Heiss; Darryl Johnson; Parastoo Azadi; Carl Bergmann; Ron Orlando; Charles T Esmon; Job Harenberg; Kelley Moremen; Lianchun Wang
Journal:  Glycobiology       Date:  2012-05-28       Impact factor: 4.313

4.  Chemoenzymatic synthesis of heparin oligosaccharides with both anti-factor Xa and anti-factor IIa activities.

Authors:  Yongmei Xu; Elizabeth H Pempe; Jian Liu
Journal:  J Biol Chem       Date:  2012-07-06       Impact factor: 5.157

5.  Anti-thrombin activities of heparin. Effect of saccharide chain length on thrombin inhibition by heparin cofactor II and by antithrombin.

Authors:  B Bray; D A Lane; J M Freyssinet; G Pejler; U Lindahl
Journal:  Biochem J       Date:  1989-08-15       Impact factor: 3.857

Review 6.  Tissue Engineering at the Blood-Contacting Surface: A Review of Challenges and Strategies in Vascular Graft Development.

Authors:  Daniel Radke; Wenkai Jia; Dhavan Sharma; Kemin Fena; Guifang Wang; Jeremy Goldman; Feng Zhao
Journal:  Adv Healthc Mater       Date:  2018-05-07       Impact factor: 9.933

7.  Heparin resistance in acute coronary syndromes.

Authors:  Jonathan D Rich; John M Maraganore; Edward Young; Rosa-Maria Lidon; Burt Adelman; Paul Bourdon; Supoat Charenkavanich; Jack Hirsh; Pierre Theroux; Christopher P Cannon
Journal:  J Thromb Thrombolysis       Date:  2007-01-13       Impact factor: 2.300

Review 8.  Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  David A Garcia; Trevor P Baglin; Jeffrey I Weitz; Meyer Michel Samama
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 9.  Sulfated Non-Saccharide Glycosaminoglycan Mimetics as Novel Drug Discovery Platform for Various Pathologies.

Authors:  Daniel K Afosah; Rami A Al-Horani
Journal:  Curr Med Chem       Date:  2020       Impact factor: 4.530

Review 10.  Anticoagulation therapy in children.

Authors:  Milind D Ronghe; Christina Halsey; Nicholas J Goulden
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.